Table 5.

Top 5 pathways related to the best target candidates of the miRNAs differentially expressed between HFS and CIN 3.

Pathway	Genes	p value∗
FoxO signaling pathway	CDKN1A, CDKN1B, PTEN, PIK3CB, STK11, CCND1, EP300, HRAS, TGFBR2, PIK3CA, EGFR, NRAS, MAPK1, SMAD2, SMAD4, STAT3, MDM2, KRAS, ATM	p < 0.001
MicroRNAs in cancer	CDKN1A, CDKN1B, PTEN, BRCA1, CCND1, MYC, EP300, HRAS, TP63, PIK3CA, CCNE1, MET, TP53, NOTCH2, NOTCH1, EGFR, NRAS, SOCS1, ABL1, MAPK1, STAT3, APC, BCL2, MDM2, KRAS, ATM	p < 0.001
PI3K-Akt signaling pathway	CDKN1A, CDKN1B, FLT4, PTEN, PIK3CB, BRCA1, CCND3, STK11, CCND1, MYC, MYB, HRAS, HSP90AA1, PIK3CA, CCNE1, MET, TP53, EGFR, NRAS, MAPK1, IL2, CDK4, BCL2, MDM2, KRAS	p < 0.001
MAPK signaling pathways	RB1, CDKN1A, CDKN1B, CCND3, CCND1, MYC, CHEK2, EP300, CCNE1, TP53, ABL1, SMAD2, SMAD4, CDK4, MDM2, ATM	p < 0.001
Intrinsic apoptosis pathways	PIK3CB, HRAS, PIK3CA, DDIT3, TP53, NRAS, MAPK1, JUN, BCL2, FAS, BAX, KRAS, ATM	p < 0.001

^∗False discovery rate-corrected (FDR-corrected) p value lower than 0.05 was used to identify the molecular cervical cancer pathways.